Matches in SemOpenAlex for { <https://semopenalex.org/work/W1985876800> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W1985876800 endingPage "1645" @default.
- W1985876800 startingPage "1645" @default.
- W1985876800 abstract "We read with interest that Scherzer et al. demonstrated that slow-responder patients with an interleukin-28B (IL-28B) rs12979860 T allele benefited from therapy extension. The investigators state that to “…(their) knowledge, such clear evidence of an association between relapse and rs12979860 genotype has not been reported previously.” 1 However, we published similar findings 3 months before, from a U.S. trial of slow responders to pegylated interferon (Peg-IFN) alpha-2b and ribavirin (RBV). 2, 3 After institutional review board approval, 90 patients participated by providing additional informed consent for genetic testing. These patients represented 89% of our slow-responding patients from our original trial. 2 The findings are shown below. In short, slow-responding patients to Peg-IFN/RBV benefit from treatment extension to 72 weeks, by virtue of diminished rates of relapse, if they harbor any non-CC genotype (i.e., IL-28B major mutation). We believe the investigators were inadvertently unaware of our findings because of nearly concurrent submission times. However, we are writing to inform your readers that the HEPATOLOGY data are confirmatory, which have now been demonstrated, albeit retrospectively, in two disparate slow-responding populations. Brian L. Pearlman M.D., F.A.C.P.* , Carole Ehleben Ed.D. , * Center for Hepatitis C, Atlanta Medical Center, Atlanta GA, Medical College of Georgia, Augusta GA, Emory School of Medicine, Atlanta GA." @default.
- W1985876800 created "2016-06-24" @default.
- W1985876800 creator A5043998553 @default.
- W1985876800 creator A5052561903 @default.
- W1985876800 date "2012-04-19" @default.
- W1985876800 modified "2023-09-23" @default.
- W1985876800 title "Effect of interleukin-28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with pegylated interferon alpha-2a/ribavirin" @default.
- W1985876800 cites W2030341869 @default.
- W1985876800 cites W2031293151 @default.
- W1985876800 cites W2165880492 @default.
- W1985876800 doi "https://doi.org/10.1002/hep.25552" @default.
- W1985876800 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22212908" @default.
- W1985876800 hasPublicationYear "2012" @default.
- W1985876800 type Work @default.
- W1985876800 sameAs 1985876800 @default.
- W1985876800 citedByCount "0" @default.
- W1985876800 crossrefType "journal-article" @default.
- W1985876800 hasAuthorship W1985876800A5043998553 @default.
- W1985876800 hasAuthorship W1985876800A5052561903 @default.
- W1985876800 hasBestOaLocation W19858768001 @default.
- W1985876800 hasConcept C126322002 @default.
- W1985876800 hasConcept C203014093 @default.
- W1985876800 hasConcept C2522874641 @default.
- W1985876800 hasConcept C2776178377 @default.
- W1985876800 hasConcept C2776408679 @default.
- W1985876800 hasConcept C2776455275 @default.
- W1985876800 hasConcept C2776461080 @default.
- W1985876800 hasConcept C2780040827 @default.
- W1985876800 hasConcept C2781399841 @default.
- W1985876800 hasConcept C2909179924 @default.
- W1985876800 hasConcept C41260117 @default.
- W1985876800 hasConcept C512399662 @default.
- W1985876800 hasConcept C71924100 @default.
- W1985876800 hasConcept C90924648 @default.
- W1985876800 hasConceptScore W1985876800C126322002 @default.
- W1985876800 hasConceptScore W1985876800C203014093 @default.
- W1985876800 hasConceptScore W1985876800C2522874641 @default.
- W1985876800 hasConceptScore W1985876800C2776178377 @default.
- W1985876800 hasConceptScore W1985876800C2776408679 @default.
- W1985876800 hasConceptScore W1985876800C2776455275 @default.
- W1985876800 hasConceptScore W1985876800C2776461080 @default.
- W1985876800 hasConceptScore W1985876800C2780040827 @default.
- W1985876800 hasConceptScore W1985876800C2781399841 @default.
- W1985876800 hasConceptScore W1985876800C2909179924 @default.
- W1985876800 hasConceptScore W1985876800C41260117 @default.
- W1985876800 hasConceptScore W1985876800C512399662 @default.
- W1985876800 hasConceptScore W1985876800C71924100 @default.
- W1985876800 hasConceptScore W1985876800C90924648 @default.
- W1985876800 hasIssue "5" @default.
- W1985876800 hasLocation W19858768001 @default.
- W1985876800 hasLocation W19858768002 @default.
- W1985876800 hasOpenAccess W1985876800 @default.
- W1985876800 hasPrimaryLocation W19858768001 @default.
- W1985876800 hasRelatedWork W1994642708 @default.
- W1985876800 hasRelatedWork W2032094407 @default.
- W1985876800 hasRelatedWork W2034422153 @default.
- W1985876800 hasRelatedWork W2059421866 @default.
- W1985876800 hasRelatedWork W2086414517 @default.
- W1985876800 hasRelatedWork W2118320797 @default.
- W1985876800 hasRelatedWork W2141168642 @default.
- W1985876800 hasRelatedWork W2167927847 @default.
- W1985876800 hasRelatedWork W2535226773 @default.
- W1985876800 hasRelatedWork W2915136652 @default.
- W1985876800 hasVolume "55" @default.
- W1985876800 isParatext "false" @default.
- W1985876800 isRetracted "false" @default.
- W1985876800 magId "1985876800" @default.
- W1985876800 workType "article" @default.